Cargando…

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod

INTRODUCTION: Real-world clinical data suggest an attenuated short-term humoral response to SARS-CoV-2 vaccines in patients with multiple sclerosis (pwMS) receiving high efficacy (HE) disease modifying therapies (DMTs) such as Ocrelizumab (OCR) and Fingolimod (FNG). Long-term humoral response in pwM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capuano, Rocco, Bisecco, Alvino, Conte, Miriana, Donnarumma, Giovanna, Altieri, Manuela, Grimaldi, Elena, Franci, Gianluigi, Chianese, Annalisa, Galdiero, Massimiliano, Coppola, Nicola, Tedeschi, Gioacchino, Gallo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895707/ https://www.ncbi.nlm.nih.gov/pubmed/35272145 http://dx.doi.org/10.1016/j.msard.2022.103724

Ejemplares similares

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
por: Altieri, Manuela, et al.
Publicado: (2022)

Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
por: Capuano, Rocco, et al.
Publicado: (2021)

Psychological consequences of COVID-19 pandemic on people with multiple sclerosis: A meta-analytic study
por: Altieri, Manuela, et al.
Publicado: (2021)

The psychological impact of Covid-19 pandemic on people with Multiple Sclerosis: A meta-analysis
por: Altieri, Manuela, et al.
Publicado: (2022)

Persistent aura-like visual phenomenon as the unique manifestation of COVID-19 post-infectious white matter lesion: A case report
por: Matrone, Federica, et al.
Publicado: (2021)

Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience?
por: Capuano, Rocco, et al.
Publicado: (2020)

Functional Plasticity of the Visual System in Multiple Sclerosis
por: Gallo, Antonio, et al.
Publicado: (2015)

Epidemiologic Data of Vitamin D Deficiency and Its Implication in Cardio-Cerebrovascular Risk in a Southern Italian Population
por: Capuano, Rocco, et al.
Publicado: (2021)

Prevalence and Distribution of High- and Low- Risk HPV Genotypes in Women Living in the Metropolitan Area of Naples: A Recent Update
por: Serretiello, Enrica, et al.
Publicado: (2023)

Resting-State Functional Correlates of Social Cognition in Multiple Sclerosis: An Explorative Study
por: Bisecco, Alvino, et al.
Publicado: (2020)

Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study
por: Lanzillo, Roberta, et al.
Publicado: (2022)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Application of Dendrimers for Treating Parasitic Diseases
por: Folliero, Veronica, et al.
Publicado: (2021)

Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives
por: Chianese, Annalisa, et al.
Publicado: (2021)

The Broad-Spectrum Antiviral Potential of the Amphibian Peptide AR-23
por: Chianese, Annalisa, et al.
Publicado: (2022)

Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases
por: Schmidt, Stephan, et al.
Publicado: (2019)

Prediction of the information processing speed performance in multiple sclerosis using a machine learning approach in a large multicenter magnetic resonance imaging data set
por: Marzi, Chiara, et al.
Publicado: (2022)

Prevalence and Antimicrobial Susceptibility Patterns of Bacterial Pathogens in Urinary Tract Infections in University Hospital of Campania “Luigi Vanvitelli” between 2017 and 2018
por: Folliero, Veronica, et al.
Publicado: (2020)

Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
por: Russo, Antonio, et al.
Publicado: (2020)

Regulation of m6A Methylation as a New Therapeutic Option against COVID-19
por: Zannella, Carla, et al.
Publicado: (2021)

Inhibitory Effect of Ophthalmic Solutions against SARS-CoV-2: A Preventive Action to Block the Viral Transmission?
por: Petrillo, Francesco, et al.
Publicado: (2021)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

Investigation of biocidal efficacy of commercial disinfectants used in public, private and workplaces during the pandemic event of SARS-CoV-2
por: Ambrosino, Annalisa, et al.
Publicado: (2022)

Stimulated single-fiber electromyography (sSFEMG) in Lambert-Eaton syndrome
por: Todisco, Vincenzo, et al.
Publicado: (2018)

Hylin-a1: A Host Defense Peptide with Antibacterial Potential against Staphylococcus aureus Multi-Resistant Strains
por: Chianese, Annalisa, et al.
Publicado: (2023)

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience
por: S., Guerrieri, et al.
Publicado: (2021)

Ophthalmic Solutions with a Broad Antiviral Action: Evaluation of Their Potential against Ocular Herpetic Infections
por: Zannella, Carla, et al.
Publicado: (2022)

Antiviral Activity of the Rhamnolipids Mixture from the Antarctic Bacterium Pseudomonas gessardii M15 against Herpes Simplex Viruses and Coronaviruses
por: Giugliano, Rosa, et al.
Publicado: (2021)

Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab
por: Katz, J.D., et al.
Publicado: (2022)

Galdieria sulphuraria: An Extremophilic Alga as a Source of Antiviral Bioactive Compounds
por: Ambrosino, Annalisa, et al.
Publicado: (2023)

Apathy Is Correlated with Widespread Diffusion Tensor Imaging (DTI) Impairment in Amyotrophic Lateral Sclerosis
por: Femiano, Cinzia, et al.
Publicado: (2018)

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program
por: Emery, Paul, et al.
Publicado: (2014)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Antiviral Peptides Delivered by Chitosan-Based Nanoparticles to Neutralize SARS-CoV-2 and HCoV-OC43
por: Mali, Avinash, et al.
Publicado: (2023)

Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine
por: Conway, Sarah, et al.
Publicado: (2023)

Ocrelizumab-Induced Severe Colitis
por: Lee, Hsing Hwa, et al.
Publicado: (2020)

Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide
por: Bollo, Luca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t8k9kasb51r5ae04ir3lbndn40